Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C

Hepatology

Volumn 59, Issue 2, 2014, Pages 453-460

  Dunn, Winston ^a   O'Neil, Maura ^a   Zhao, Jie ^a   Wu, Chuang Hong ^a   Roberts, Benjamin ^a   Chakraborty, Shweta ^a   Sherman, Craig ^a   Weaver, Brandy ^a   Taylor, Ryan ^a   Olson, Jody ^a   Olyaee, Mojtaba ^a   Gilroy, Richard ^a   Schmitt, Timothy ^a   Wan, Yu Jui Yvonne ^a   Weinman, Steven A ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; END STAGE LIVER DISEASE; EXPLANT; FEMALE; FOLLOW UP; GENE; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; HCV DONOR RISK INDEX; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ORGAN DONOR; OUTCOME ASSESSMENT; PATATIN LIKE PHOSPHOLIPASE 3 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURGICAL MORTALITY; VIRUS LOAD;

BIOPSY; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS C; HUMANS; LIPASE; LIVER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TISSUE DONORS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84893674025     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26758     Document Type: Article

References (33)

1. Shiffman ML, Stravitz RT, Contos MJ, Mills AS, Sterling RK, Luketic VA, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004;10:1248-1255.
2. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S28-S34.
3. Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004;10:340-346.
4. McLauchlan J. Lipid droplets and hepatitis C virus infection. Biochim Biophys Acta 2009;1791:552-559.
5. Robinson JL, Doucette K. The natural history of hepatitis C virus infection acquired during childhood. Liver Int 2012;32:258-270.
6. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-1217.
7. Sookoian S, Castano GO, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009;50:2111-2116.
8. Sookoian S, Castano GO, Burgueno AL, Fernandez Gianotti T, Rosselli MS, Pirola CJ. A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009;50:2111-2116.
9. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010;285:6706-6715.
10. Romeo S, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol 2010;21:247-252.
11. Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. Characterization of the human patatin-like phospholipase family. J Lipid Res 2006;47:1940-1949.
12. do ON, Eurich D, Trautwein C, Neuhaus P, Neumann UP, Wasmuth HE. The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C. Hepatology 2011;54:1483-1484.
13. Maganty K, Levi D, Moon J, Bejarano PA, Arosemena L, Tzakis A, et al. Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation. Dig Dis Sci 2010;55:3597-3601.
14. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
15. Valenti L, Aghemo A, Stattermayer AF, Maggioni P, De Nicola S, Motta BM, et al. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther 2012;35:1434-1442.
16. Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl 2010;16:943-949.
17. Deschenes M, Belle SH, Krom RA, Zetterman RK, Lake JR. Early allograft dysfunction after liver transplantation: a definition and predictors of outcome. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transplantation 1998;66:302-310.
18. Wagener G, Raffel B, Young AT, Minhaz M, Emond J. Predicting early allograft failure and mortality after liver transplantation: the role of the postoperative model for end-stage liver disease score. Liver Transpl 2013;19:534-542.
19. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
20. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894-903.
21. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010;42:21-23.
22. Cai T, Dufour JF, Muellhaupt B, Gerlach T, Heim M, Moradpour D, et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol 2011;55:529-535.
23. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, De Nicola S, et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 2011;53:791-799.
24. Corradini SG, Burza MA, Molinaro A, Romeo S. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology 2011;53:1776; author reply 1777.
25. Trepo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011;54:60-69.
26. Chen W, Chang B, Li L, Chan L. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology 2010;52:1134-1142.
27. Finkenstedt A, Auer C, Glodny B, Posch U, Steitzer H, Lanzer G, et al. PNPLA3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 2013 [Epub ahead of print].
28. Watt KD, Dierkhising R, Fan C, Heimbach JK, Tillman H, Goldstein D, et al. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant 2013;13:2450-2457.
29. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9:651-663.
30. Loinaz C, Gonzalez EM. Marginal donors in liver transplantation. Hepatogastroenterology 2000;47:256-263.
31. Marsman WA, Wiesner RH, Rodriguez L, Batts KP, Porayko MK, Hay JE, et al. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996;62:1246-1251.
32. Doyle MB, Vachharajani N, Wellen JR, Anderson CD, Lowell JA, Shenoy S, et al. Short- and long-term outcomes after steatotic liver transplantation. Arch Surg 2010;145:653-660.
33. Subramanian V, Seetharam AB, Vachharajani N, Tiriveedhi V, Angaswamy N, Ramachandran S, et al. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation 2011;92:1259-1268.